Compare Lockheed Martin Corporation (LMT) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Revvity Inc — how do they compare? Lockheed Martin Corporation trades at $509.59 (market cap $117.22B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Lockheed Martin Corporation is far larger — about 6.9× Revvity Inc's market cap, and Lockheed Martin Corporation pays the higher dividend (2.72%). Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and Revvity Inc for 12 Days on average.
| LMT | RVTY | |
|---|---|---|
Market Cap | $117.22B | $16.98B |
Volume | 1,101,121 | 1,456,900 |
Sector | Industrials | Health |
52-Week High | $676.70 | $157.36 |
52-Week Low | $439.19 | $82.26 |
Typical Hold Time | 86 Days | 12 Days |
Enterprise Value | $133.96B | $19.30B |
Dividend Yield | 2.72% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $507.89, up 1.74% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS beat but missed Q1 and Q4 2025 expectations, with revenue growth from $75.05B in 2025 to projected $77.0B in 2026. Recent news highlights AI integration and F-35 program developments, while analyst consensus remains strongly bullish with a $635.33 price target.
LMT offers stable defense sector exposure with 23 consecutive dividend increases and strong cash flow, but faces execution risks on fixed-price contracts and competitive pressures. The stock trades at reasonable valuations (P/E 18.73, P/S 1.53) with high institutional support, though technical weakness near support at $503 requires monitoring for sustained upward momentum.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
